NASDAQ:HALO

Halozyme Therapeutics - HALO News Today

$33.68

+0.82 (+2.50%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: $32.86
▼
$33.85
50-Day Range: $32.86
▼
$53.28
52-Week Range: $32.83
▼
$59.46

Volume: 2.35 million shs
Average Volume: 1.56 million shs
Market Capitalization: $4.56 billion

P/E Ratio: 23.23
Dividend Yield: N/A
Price Target: $56.13

Institutional Ownership

Get Halozyme Therapeutics News Delivered to You Automatically

HALO Media Mentions By Week

HALO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HALO
News Sentiment
▼
0.08

0.35
▲
Average
Medical
News Sentiment

HALO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HALO Articles
This Week
▼
17

3
▲
HALO Articles
Average Week

Source

Source	Headline
	First Hawaiian Bank Has $1.55 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) marketbeat.com - March 22 at 5:52 AM
	Titleist Asset Management LTD. Invests $273,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) marketbeat.com - March 21 at 7:49 AM
	Halozyme Therapeutics, Inc. Forecasted to Post Q3 2023 Earnings of $0.66 Per Share (NASDAQ:HALO) marketbeat.com - March 20 at 1:46 AM
	Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound? finance.yahoo.com - March 23 at 5:54 PM
	Halozyme Therapeutics, Inc. to Post Q3 2023 Earnings of $0.66 Per Share, SVB Leerink Forecasts (NASDAQ:HALO) americanbankingnews.com - March 22 at 1:54 AM
	Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength? finance.yahoo.com - March 21 at 7:53 AM
	Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year Low Following Analyst Downgrade americanbankingnews.com - March 19 at 1:24 AM
	SVB Leerink Downgrades Halozyme Therapeutics to Market Perform, Announces $42 Price Target benzinga.com - March 18 at 8:51 PM
	Halozyme Therapeutics, Inc. Forecasted to Post Q4 2023 Earnings of $0.78 Per Share (NASDAQ:HALO) americanbankingnews.com - March 17 at 7:36 AM
	Halozyme Therapeutics' (HALO) Market Perform Rating Reaffirmed at SVB Leerink americanbankingnews.com - March 17 at 6:46 AM
	SVB Leerink Downgrades Halozyme Therapeutics (HALO) msn.com - March 16 at 7:31 PM
	The Latest Analyst Ratings for Halozyme Therapeutics msn.com - March 16 at 2:31 PM
	Dow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan finance.yahoo.com - March 16 at 2:31 PM
	Global Hyaluronidase Market Size by Application (Dermatology, Plastic Surgery) Forecast from 2023 to 2028 marketwatch.com - March 15 at 1:54 PM
	Halozyme sees no impact on royalties after EU body revokes J&J's Darzalex patent msn.com - March 15 at 1:54 PM
	HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE finance.yahoo.com - March 15 at 8:53 AM
	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages americanbankingnews.com - March 15 at 3:48 AM
	Halozyme Therapeutics Stock (NASDAQ:HALO), Guidance and Forecast benzinga.com - March 14 at 5:38 AM
	Halozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions benzinga.com - March 13 at 7:37 PM
	Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options finance.yahoo.com - March 13 at 7:37 PM
	Antidiabetic Drug Market to 2023-2028 marketwatch.com - March 10 at 3:44 AM
	Halozyme Therapeutics: A Trailblazer, But With Lukewarm Financials seekingalpha.com - February 26 at 8:03 AM
	JP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $52 benzinga.com - February 25 at 4:30 PM
	Halozyme Therapeutics Q4 EPS $0.42 Misses $0.47 Estimate, Sales $181.50M Miss $192.05M Estimate benzinga.com - February 23 at 4:09 PM
	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS finance.yahoo.com - February 21 at 9:29 PM
	BlackRock Increases Position in Halozyme Therapeutics 247wallst.com - February 15 at 10:31 AM
	Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? finance.yahoo.com - February 10 at 1:52 PM
	Halozyme Appoints Barbara Duncan to its Board of Directors finance.yahoo.com - February 6 at 9:37 AM
	Hyaluronidase Market Size in 2023 Industry Demand, Industry News, Business Growth, Top Key Players Update till 2028 marketwatch.com - January 30 at 4:49 AM
	Multiple Reasons For the Outperformance of Halozyme Therapeutics (HALO) finance.yahoo.com - January 23 at 8:44 AM
	Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance finance.yahoo.com - January 12 at 2:59 PM
	HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024 finance.yahoo.com - January 11 at 1:21 PM
	Antidiabetic Drug Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028 marketwatch.com - January 11 at 12:56 AM
	JMP Securities Keeps Their Buy Rating on Halozyme (HALO) markets.businessinsider.com - January 11 at 12:56 AM
	Halozyme Provides 2023 Financial Guidance and Outlook finance.yahoo.com - January 10 at 7:55 PM
	Halo Therapeutics stock drops following weak 2023 outlook finance.yahoo.com - January 10 at 7:55 PM
	Halozyme Therapeutics: Chugging Along seekingalpha.com - January 9 at 10:46 PM
	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term finance.yahoo.com - January 4 at 1:13 PM
	Investors in Halozyme Therapeutics (NASDAQ:HALO) have made a solid return of 219% over the past three years finance.yahoo.com - January 3 at 10:06 AM
	Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 3 at 10:06 AM
	Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology msn.com - December 21 at 3:31 PM
	Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio finance.yahoo.com - December 19 at 10:05 AM
	Antidiabetic Drug Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 Impact marketwatch.com - December 12 at 10:46 AM
	Where Halozyme Therapeutics Stands With Analysts markets.businessinsider.com - December 8 at 3:50 PM
	Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue? finance.yahoo.com - December 8 at 3:50 PM
	5 Analysts Have This to Say About Halozyme Therapeutics markets.businessinsider.com - December 8 at 9:18 AM
	Estimating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) finance.yahoo.com - December 7 at 7:23 AM
	LPCN: Focus on CNS Disorders finance.yahoo.com - November 30 at 11:56 AM
	11 Best Diabetes Stocks To Buy Now finance.yahoo.com - November 27 at 5:48 PM
	4 Analysts Have This to Say About Halozyme Therapeutics markets.businessinsider.com - November 22 at 6:14 PM
	HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth finance.yahoo.com - November 15 at 3:03 PM
	Should You Hold Halozyme Therapeutics (HALO)? finance.yahoo.com - November 15 at 10:03 AM
	Interview With Quoc Tran of Tran Capital finance.yahoo.com - November 11 at 5:57 PM

Get Halozyme Therapeutics News Delivered to You Automatically

This page (NASDAQ:HALO) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Halozyme Therapeutics - HALO News Today

HALO Media Mentions By Week

HALO Media Sentiment

HALO News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info